William Blackstock

Summary

Affiliation: Wake Forest University School of Medicine
Country: USA

Publications

  1. ncbi request reprint Outcomes among African-American/non-African-American patients with advanced non-small-cell lung carcinoma: report from the Cancer and Leukemia Group B
    A William Blackstock
    Department of Radiation Oncology, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    J Natl Cancer Inst 94:284-90. 2002
  2. pmc ACR appropriateness criteria®  resectable rectal cancer
    William E Jones
    UT Health Science Center San Antonio, San Antonio, Texas, USA
    Radiat Oncol 7:161. 2012
  3. pmc Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer--a phase II study
    Shannon K Tomlinson
    Dept of Radiation Oncology, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    BMC Cancer 2:9. 2002
  4. ncbi request reprint Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer
    A W Blackstock
    Department of Radiation Oncology, Wake Forest University Baptist Medical Center, Winston Salem, NC 27516, USA
    J Clin Oncol 17:2208-12. 1999
  5. ncbi request reprint Phase Ia/Ib chemo-radiation trial of gemcitabine and dose-escalated thoracic radiation in patients with stage III A/B non-small cell lung cancer
    A William Blackstock
    Department of Radiation Oncology, Wake Forest University Comprehensive Cancer Center, Winston Salem, North Carolina 27516, USA
    J Thorac Oncol 1:434-40. 2006
  6. ncbi request reprint Pathologic complete response may not represent the optimal surrogate for survival after preoperative therapy for esophageal cancer
    A William Blackstock
    Department of Radiation Oncology, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    Int J Gastrointest Cancer 37:7-14. 2006
  7. pmc Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study
    A W Blackstock
    Department of Radiation Oncology, Wake Forest University School of Medicine, Medical Center Blvd, Winston Salem, NC 27157, USA
    Br J Cancer 95:260-5. 2006
  8. ncbi request reprint Similar outcomes between African American and non-African American patients with extensive-stage small-cell lung carcinoma: report from the Cancer and Leukemia Group B
    A William Blackstock
    Department of Radiation Oncology, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    J Clin Oncol 24:407-12. 2006
  9. ncbi request reprint A prospective evaluation of the impact of 18-F-fluoro-deoxy-D-glucose positron emission tomography staging on survival for patients with locally advanced esophageal cancer
    A William Blackstock
    Department of Radiation Oncology, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    Int J Radiat Oncol Biol Phys 64:455-60. 2006
  10. ncbi request reprint Split-course versus continuous thoracic radiation therapy for limited-stage small-cell lung cancer: final report of a randomized phase III trial
    A William Blackstock
    Department of Radiation Oncology, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    Clin Lung Cancer 6:287-92. 2005

Research Grants

  1. Cytokines in radiation lung injury
    ARTHUR BLACKSTOCK; Fiscal Year: 2003

Detail Information

Publications39

  1. ncbi request reprint Outcomes among African-American/non-African-American patients with advanced non-small-cell lung carcinoma: report from the Cancer and Leukemia Group B
    A William Blackstock
    Department of Radiation Oncology, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    J Natl Cancer Inst 94:284-90. 2002
    ..We investigated whether the disparity in survival would persist when patients were treated with similar systemic therapies (i.e., in phase II and phase III Cancer and Leukemia Group B [CALGB] trials)...
  2. pmc ACR appropriateness criteria®  resectable rectal cancer
    William E Jones
    UT Health Science Center San Antonio, San Antonio, Texas, USA
    Radiat Oncol 7:161. 2012
    ..In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment...
  3. pmc Schedule-selective biochemical modulation of 5-fluorouracil in advanced colorectal cancer--a phase II study
    Shannon K Tomlinson
    Dept of Radiation Oncology, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    BMC Cancer 2:9. 2002
    ..This phase II study was initiated to determine the activity and toxicity of sequential methotrexate--leucovorin and 5-fluorouracil chemotherapy in patients with advanced colorectal cancer...
  4. ncbi request reprint Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer
    A W Blackstock
    Department of Radiation Oncology, Wake Forest University Baptist Medical Center, Winston Salem, NC 27516, USA
    J Clin Oncol 17:2208-12. 1999
    ..To determine the maximum-tolerated dose, dose-limiting toxicities, and potential antitumor activity of twice-weekly gemcitabine and concurrent radiation in patients with locally advanced pancreatic cancer...
  5. ncbi request reprint Phase Ia/Ib chemo-radiation trial of gemcitabine and dose-escalated thoracic radiation in patients with stage III A/B non-small cell lung cancer
    A William Blackstock
    Department of Radiation Oncology, Wake Forest University Comprehensive Cancer Center, Winston Salem, North Carolina 27516, USA
    J Thorac Oncol 1:434-40. 2006
    ..The safety of dose-escalated thoracic radiation concurrent with gemcitabine in patients with inoperable stage III non-small cell lung cancer has not been studied...
  6. ncbi request reprint Pathologic complete response may not represent the optimal surrogate for survival after preoperative therapy for esophageal cancer
    A William Blackstock
    Department of Radiation Oncology, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    Int J Gastrointest Cancer 37:7-14. 2006
    ..We designed a phase II trial to examine the benefit of preoperative hyperfractionated radiation therapy (XRT) and concurrent chemotherapy for patients with locally advanced esophageal cancer (LAEC)...
  7. pmc Adjuvant gemcitabine and concurrent radiation for patients with resected pancreatic cancer: a phase II study
    A W Blackstock
    Department of Radiation Oncology, Wake Forest University School of Medicine, Medical Center Blvd, Winston Salem, NC 27157, USA
    Br J Cancer 95:260-5. 2006
    ..These results confirm the feasibility of delivering adjuvant concurrent gemcitabine and radiation to the upper abdomen. This strategy produced good local regional tumour control...
  8. ncbi request reprint Similar outcomes between African American and non-African American patients with extensive-stage small-cell lung carcinoma: report from the Cancer and Leukemia Group B
    A William Blackstock
    Department of Radiation Oncology, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    J Clin Oncol 24:407-12. 2006
    ..We investigated whether the disparity in survival would persist when patients were treated with similar therapies (ie, phase II/III Cancer and Leukemia Group B [CALGB] trials)...
  9. ncbi request reprint A prospective evaluation of the impact of 18-F-fluoro-deoxy-D-glucose positron emission tomography staging on survival for patients with locally advanced esophageal cancer
    A William Blackstock
    Department of Radiation Oncology, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    Int J Radiat Oncol Biol Phys 64:455-60. 2006
    ..To determine the impact of 18-F-fluoro-deoxy-D-glucose positron emission tomography (FDG-PET) in the staging and prognosis of patients with locally advanced esophageal cancer (LAEC)...
  10. ncbi request reprint Split-course versus continuous thoracic radiation therapy for limited-stage small-cell lung cancer: final report of a randomized phase III trial
    A William Blackstock
    Department of Radiation Oncology, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    Clin Lung Cancer 6:287-92. 2005
    ..Interdigitating split-course thoracic RT delivered in 2.5-Gy fractions was tolerable in patients with limited-stage SCLC but did not provide a survival advantage...
  11. ncbi request reprint Tumor uptake and elimination of 2',2'-difluoro-2'-deoxycytidine (gemcitabine) after deoxycytidine kinase gene transfer: correlation with in vivo tumor response
    A W Blackstock
    Department of Radiation Oncology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, NC 27156, USA
    Clin Cancer Res 7:3263-8. 2001
    ..To test this hypothesis, we examined dFdCyd/dFdCTP uptake and clearance in HT-29 human colon carcinoma xenografts in nude mice by high-performance liquid chromatography (HPLC) and fluorine-19 magnetic resonance spectroscopy (F-19 MRS)...
  12. ncbi request reprint Phase I study of twice-weekly gemcitabine and concurrent thoracic radiation for patients with locally advanced non-small-cell lung cancer
    A W Blackstock
    Wake Forest University Baptist Medical Center, Winston Salem, NC, USA
    Int J Radiat Oncol Biol Phys 51:1281-9. 2001
    ..To determine the maximum tolerated dose (MTD) and dose-limiting toxicity of twice-weekly gemcitabine and concurrent thoracic radiation in patients with Stage IIIa/IIIb non-small-cell lung cancer (NSCLC)...
  13. ncbi request reprint Cancer and leukemia group B (CALGB) 89805: phase II chemoradiation trial using gemcitabine in patients with locoregional adenocarcinoma of the pancreas
    A William Blackstock
    Radiation Oncology, Wake Forest University Comprehensive Cancer Center, Winston Salem, NC 277516, USA
    Int J Gastrointest Cancer 34:107-16. 2003
    ..Determine the safety and efficacy of twice weekly gemcitabine and concurrent radiation to the upper abdomen followed by weekly gemcitabine in patients with surgically staged, locally advanced pancreatic cancer...
  14. pmc Outcomes of patients with esophageal cancer staged with [¹⁸F]fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection?
    Arta Monir Monjazeb
    Wake Forest University Health Sciences, Winston Salem, NC 27103, USA
    J Clin Oncol 28:4714-21. 2010
    ..To determine whether [(18)F]fluorodeoxyglucose positron emission tomography (FDG-PET) can delineate patients with esophageal cancer who may not benefit from esophagectomy after chemoradiotherapy...
  15. ncbi request reprint Small cell lung cancer: have we made any progress over the last 25 years?
    Brian E Lally
    Department of Radiation Oncology, Wake Forest University Health Sciences, Winston Salem, North Carolina, USA
    Oncologist 12:1096-104. 2007
    ..It is imperative that, whenever possible, patients be given the opportunity to participate in future clinical trials so that the survival for these patients can continue to improve...
  16. ncbi request reprint Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium
    Lawrence B Marks
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
    J Clin Oncol 22:4329-40. 2004
    ..6 Gy bid) for unresectable locally advanced lung cancer (IIB to IIIA/B) following induction carboplatin/paclitaxel (C/T) or carboplatin/vinorelbine (C/N)...
  17. ncbi request reprint Phase II trial of induction gemcitabine/CPT-11 followed by a twice-weekly infusion of gemcitabine and concurrent external beam radiation for the treatment of locally advanced pancreatic cancer
    Girish Mishra
    Division of Gastroenterology, Comprehensive Cancer Center, Wake Forest University, Winston Salem, North Carolina 27516, USA
    Am J Clin Oncol 28:345-50. 2005
    ..This phase II trial of induction irinotecan/gemcitabine followed by twice-weekly gemcitabine and upper abdominal radiation was initiated to determine the activity of this regimen in patients with unresectable pancreatic cancer...
  18. ncbi request reprint Irinotecan/gemcitabine followed by twice-weekly gemcitabine/radiation in locally advanced pancreatic cancer
    A William Blackstock
    Department of Radiation Oncology, Comprehensive Cancer Center of Wake Forest University, Winston Salem, North Carolina 27157, USA
    Oncology (Williston Park) 16:25-8. 2002
    ..These preliminary data suggest that this regimen is well tolerated. Although the data are limited, tumor progression during the induction chemotherapy has not been observed thus far (radiographically or biochemically [CA-19-9])...
  19. ncbi request reprint Chemoradiation with novel agents for rectal cancer
    Kevin P McMullen
    Department of Radiation Oncology, Wake Forest University School of Medicine, Medical Center Blvd, Winston Salem, NC 27157, USA
    Clin Colorectal Cancer 2:24-30. 2002
    ..In this review, we discuss the use of novel anticancer agents in combination with radiation therapy for the treatment of locally advanced rectal cancer...
  20. ncbi request reprint Long-term results of local excision with and without chemoradiation for adenocarcinoma of the rectum
    Stacy Wentworth
    Department of Radiation Oncology, Comprehensive Cancer Center, Wake Forest University School of Medicine, Winston Salem, NC 27157 1030, USA
    Clin Colorectal Cancer 4:332-5. 2005
    ....
  21. ncbi request reprint Rectal cancer: adjuvant therapy and new directions
    Kevin P McMullen
    Radiation Oncology, Comprehensive Cancer Center of Wake Forest University, Winston Salem, North Carolina, USA
    Rev Recent Clin Trials 2:27-32. 2007
    ..Further work is required regarding the rational integration of these targeted agents and the optimal selection of patients that will most likely benefit...
  22. ncbi request reprint Radiation safety issues with positron-emission/computed tomography simulation for stereotactic body radiation therapy
    William T Kearns
    Department of Radiation Oncology, Wake Forest University Baptist Medical Center, Winston Salem, NC, USA
    J Appl Clin Med Phys 9:2763. 2008
    ..The PET/CT-based SBRT simulations are safe and important for treatment planning that optimizes biologic dose distribution with highly accurate and reproducible target definition...
  23. doi request reprint Multidisciplinary treatment of resectable rectal cancer
    Diandra N Ayala
    Comprehensive Cancer Center of Wake Forest University, Winston Salem, NC, USA
    Expert Rev Gastroenterol Hepatol 3:383-94. 2009
    ..Future trials should aim to address the role of adjuvant therapies utilizing new criteria, such as function, quality of life and impact on development of metastatic disease...
  24. ncbi request reprint The risk of death from heart disease in patients with nonsmall cell lung cancer who receive postoperative radiotherapy: analysis of the Surveillance, Epidemiology, and End Results database
    Brian E Lally
    Department of Radiation Oncology, Wake Forest University Health Sciences, Winston Salem, NC 27157 1030, USA
    Cancer 110:911-7. 2007
    ..This study was designed to investigate whether the mortality from heart disease, a manifestation of intercurrent disease after postoperative radiotherapy (PORT), has decreased over time for patients with nonsmall cell lung cancer (NSCLC)...
  25. pmc Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer
    Edward A Levine
    Surgical Oncology Service and the Department of General Surgery, Comprehensive Cancer Center of Wake Forest University, Winston Salem, NC 27157, USA
    Ann Surg 243:472-8. 2006
    ..To evaluate the utility of F-FDG-PET in predicting response to concomitant chemoradiation in locally-advanced esophageal cancer...
  26. pmc The role of alveolar epithelium in radiation-induced lung injury
    Celine Almeida
    Department of Radiation Oncology, Wake Forest School of Medicine, Winston Salem, North Carolina, United States of America
    PLoS ONE 8:e53628. 2013
    ....
  27. ncbi request reprint Bronchial stenosis: an underreported complication of high-dose external beam radiotherapy for lung cancer?
    Keith L Miller
    Department of Radiation Oncology, Duke University Medical Center, Durham, NC 27710, USA
    Int J Radiat Oncol Biol Phys 61:64-9. 2005
    ..To assess the incidence of clinically significant bronchial stenosis in patients treated with high doses (i.e., >70 Gy) of twice-daily external beam radiation therapy (RT)...
  28. ncbi request reprint Definitive chemoradiation for the treatment of locally advanced non small-cell lung cancer
    A William Blackstock
    Department of Radiation Oncology, Wake Forest University, Winston Salem, NC, USA
    J Clin Oncol 25:4146-52. 2007
    ..There is an urgent need to develop regimens that incorporate chemotherapy agents that can be administered at doses that are systemically active and yet tolerable...
  29. pmc Phase I study of accelerated conformal radiotherapy for stage I non-small-cell lung cancer in patients with pulmonary dysfunction: CALGB 39904
    Jeffrey A Bogart
    Department of Radiation Oncology, State University of New York Upstate Medical University, 750 E Adams St, Syracuse NY 13210, USA
    J Clin Oncol 28:202-6. 2010
    ..The optimal treatment for medically inoperable stage I non-small-cell lung cancer (NSCLC) has not been defined...
  30. ncbi request reprint Preoperative versus postoperative chemoradiotherapy in the trimodality management of esophageal cancer
    Carolyn Kim
    Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
    Clin Adv Hematol Oncol 7:327-333, 342. 2009
    ..Based on the study information currently available, we conclude that treatment options should be tailored to the individual patient...
  31. ncbi request reprint A pharmacogenomic study of docetaxel and gemcitabine for the initial treatment of advanced non-small cell lung cancer
    W Jeffrey Petty
    Department of Medicine, Section on Hematology and Oncology, Wake Forest University Health Sciences, Winston Salem, North Carolina 27157, USA
    J Thorac Oncol 2:197-202. 2007
    ..This phase II clinical trial was performed using a non-platinum-based chemotherapy doublet. The impact of previously identified polymorphisms on clinical outcomes was assessed...
  32. ncbi request reprint The mechanism of action of radiosensitization of conventional chemotherapeutic agents
    Theodore S Lawrence
    Department of Radiation Oncology, University of Michigan, Ann Arbor, MI 48109, USA
    Semin Radiat Oncol 13:13-21. 2003
    ..The identification of the enzymatic targets for these drugs offers the potential to develop predictive assays for response and to develop methods of imaging the progress of therapy...
  33. doi request reprint Trends in the outcomes for patients with limited stage small cell lung cancer: An analysis of the Surveillance, Epidemiology, and End Results database
    Brian E Lally
    Wake Forest University Health Sciences, Department of Radiation Oncology, Medical Center Boulevard, Winston Salem, NC 27157, United States
    Lung Cancer 64:226-31. 2009
    ..In order to continue to improve clinical outcomes, clinical trials investigating new treatment paradigms are needed...
  34. ncbi request reprint Determination of qualitative telomerase activity as an adjunct to the diagnosis of pancreatic adenocarcinoma by EUS-guided fine-needle aspiration
    Girish Mishra
    Department of Internal Medicine, Section of Gastroenterology, Wake Forest University School of Medicine, Medical Center Boulevard, Winston Salem, NC 27157, USA
    Gastrointest Endosc 63:648-54. 2006
    ..Telomerase activity is up-regulated in pancreatic cancer. Hence, measurement of telomerase activity in pancreatic needle-biopsy specimens could assist in establishing a positive diagnosis in specimens that are inadequate for cytology...
  35. doi request reprint ACR Appropriateness Criteria on resectable rectal cancer: expert panel on radiation oncology--rectal/anal cancer
    W Warren Suh
    Department of Radiation Oncology, Dana Farber Cancer Institute Brigham and Women s Hospital, Boston, MA 02459, USA
    Int J Radiat Oncol Biol Phys 70:1427-30. 2008
    ..A summary of the major randomized clinical trials spanning the past several decades is provided...
  36. ncbi request reprint Locally advanced pancreatic cancer: a review
    Suzanne Russo
    Baptist Centers for Cancer Care, Memphis, TN, USA
    Semin Oncol 34:327-34. 2007
    ..This review summarizes the current status, controversies, and future prospects for the treatment of locally advanced pancreatic cancer...
  37. doi request reprint Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105
    Mark A Socinski
    Lineberger Comprehensive Cancer Center, University of North Carolina Chapel Hill, NC 27599, USA
    J Clin Oncol 26:2457-63. 2008
    ..To evaluate 74 Gy thoracic radiation therapy (TRT) with induction and concurrent chemotherapy in stage IIIA/B non-small-cell lung cancer (NSCLC)...
  38. ncbi request reprint Impact of neoadjuvant therapy on postoperative complications in patients undergoing resection for rectal adenocarcinoma
    Immanuel I Turner
    Surgical Oncology Service, Wake Forest University, Winston Salem, North Carolina 27157, USA
    Am Surg 70:1045-9. 2004
    ..However, the SS group did show a trend between preoperative chemotherapy and radiation and complication rate. However, this may not outweigh the advantages of preoperative therapy in this setting...
  39. ncbi request reprint Colorectal cancer
    Sharlene Gill
    Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia
    Mayo Clin Proc 82:114-29. 2007
    ....

Research Grants1

  1. Cytokines in radiation lung injury
    ARTHUR BLACKSTOCK; Fiscal Year: 2003
    ..Even further, understanding the temporal expression of MIP-1alpha during thoracic radiation may allow the future utilization of anticytokine reagents, e.g. antibodies, receptor and synthesis blockers during treatment. ..